Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review.

AIMS To derive a more precise estimate of the prognostic significance of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters [early heart mediastinal ratio (H/M), late H/M, and myocardial washout] in heart failure (HF). METHODS AND RESULTS Eighteen studies with a total of 1755 patients, stratifying survival, and cardiac events in patients with HF by MIBG, were eligible for analysis. The pooled hazard ratio (HR) estimates for cardiac death and cardiac events associated with washout showed no significant heterogeneity and were 1.72 [95%CI (confidence interval), 1.72-2.52; P = 0.006] and 1.08 (95%CI: 1.03-1.12; P < 0.001), respectively. The pooled HR estimates for cardiac death and cardiac events associated with early H/M and late H/M showed significant heterogeneity (I2 > or = 75%). Limiting the pooling to the qualitative best three studies rendered I2 insignificant (I2 = 0) and resulted in a pooled HR of late H/M for cardiac death of 1.82 (95%CI: 0.80-4.12; P = 0.15) and for cardiac events of 1.98 (95%CI: 1.57-2.50; P < 0.001). CONCLUSION Our results indicate that patients with HF and decreased late H/M or increased myocardial MIBG washout have a worse prognosis compared with those with normal semi-quantitative myocardial MIBG parameters.

[1]  Henry Krum,et al.  The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). , 2005, European heart journal.

[2]  Harlan M Krumholz,et al.  ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society , 2005, Circulation.

[3]  M. Anastasiou-Nana,et al.  Prognostic value of iodine-123-metaiodobenzylguanidine myocardial uptake and heart rate variability in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 2005, The American journal of cardiology.

[4]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[5]  B. van Eck-Smit,et al.  Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  K. Dickstein,et al.  [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. , 2005, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[7]  Jeroen J. Bax,et al.  Cardiac Resynchronization Induces Favorable Neurohumoral Changes , 2005, Pacing and clinical electrophysiology : PACE.

[8]  T. Nakata,et al.  Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  H. Nakano,et al.  Usefulness of123I-metaiodobenzylguanidine myocardial scintigraphy in the prediction of cardiac events in patients with cardiomyopathy showing stabilization of symptoms or preserved cardiac function , 2004, Annals of nuclear medicine.

[10]  H. Nakano,et al.  Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of β-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  I. Kubota,et al.  Dynamic123I-MIBG SPECT reflects sympathetic nervous integrity and predicts clinical outcome in patients with chronic heart failure , 2004 .

[12]  T. Nakata,et al.  Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  L. Wagoner,et al.  Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. , 2003, Journal of cardiac failure.

[14]  T. Nakata,et al.  Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. , 2003, Journal of cardiac failure.

[15]  M. Kurabayashi,et al.  Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[16]  M. Kurabayashi,et al.  Effect of spironolactone on cardiacsympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy , 2003 .

[17]  Masatsugu Hori,et al.  Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. , 2003, Journal of the American College of Cardiology.

[18]  M. Kurabayashi,et al.  Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  J. Tijssen,et al.  Beneficial effects of metoprolol on myocardial sympathetic function: Evidence from a randomized, placebo-controlled study in patients with congestive heart failure. , 2002, American heart journal.

[20]  V. Hasselblad,et al.  Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma , 2002, Cancer.

[21]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[22]  J. Tijssen,et al.  Cardiac 123I-MIBG imaging and clinical variables in risk stratification in patients with heart failure treated with beta blockers , 2002, Nuclear medicine communications.

[23]  J. Kusukawa,et al.  Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments--comparison with neurohumoral factors. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[24]  S. Mochizuki,et al.  Effect of taurine on intracellular Ca handling and contractility (Ca-force-frequency relationship) in perfused rat hearts , 2002 .

[25]  M. Hori,et al.  Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study , 2001, Heart.

[26]  T. Nakata,et al.  Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  D. G. Altman Systematic reviews of evaluations of prognostic variables , 2001, BMJ : British Medical Journal.

[28]  M. Miyagawa,et al.  Prognostic value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. , 2001, Japanese circulation journal.

[29]  P. Merlet,et al.  Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  H. Kasanuki,et al.  Comparison of parameters of 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. , 1999, Nuclear medicine communications.

[31]  P. Merlet,et al.  Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. , 1999, Journal of the American College of Cardiology.

[32]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[33]  George Davey Smith,et al.  meta-analysis bias in location and selection of studies , 1998 .

[34]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[35]  K. Lie,et al.  Increased myocardial [123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. , 1996, Heart.

[36]  R. Brian Haynes,et al.  Research Paper: Performances of 27 MEDLINE systems tested by searches with clinical questions , 1994, J. Am. Medical Informatics Assoc..

[37]  P. Merlet,et al.  Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[39]  I. Kubota,et al.  Dynamic 123I-MIBG SPECT reflects sympathetic nervous integrity and predicts clinical outcome in patients with chronic heart failure. , 2004, Annals of nuclear medicine.

[40]  A. Iskandrian,et al.  MIBG imaging , 2002, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[41]  M. Egger,et al.  Bias in location and selection of studies. , 1998, BMJ.

[42]  J. Corbett,et al.  Effects of bucindolol on neurohormonal activation in congestive heart failure. , 1991, The American journal of cardiology.